[(S)-γ-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2618-2621

  Yoshida, Tomohiro ^a   Sakashita, Hiroshi ^a   Akahoshi, Fumihiko ^a   Hayashi, Yoshiharu ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

4 Arylpiperazine; DPP IV inhibitor; Thiazolidine

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PIPERAZINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROLINE DERIVATIVE; SAXAGLIPTIN; SITAGLIPTIN; THIAZOLIDINE DERIVATIVE; VILDAGLIPTIN;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PIPERAZINES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES; TIME FACTORS;

EID: 33947720282     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.110     Document Type: Article

References (22)

1. Kieffer T.J., and Habener J.F. Endocr. Rev. 20 (1999) 876
2. Drucker D.J. Diabetes 47 (1998) 159
3. Holst J.J. Curr. Med. Chem. 6 (1999) 1005
4. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6825
5. Nielsen L.L. Drug Discovery Today 10 (2005) 703
6. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. J. Med. Chem. 48 (2005) 141
7. Heins J., Welker P., Schönlein C., Born I., Hartrodt B., Neubert K., Tsuru D., and Barth A. Biochim. Biophys. Acta 954 (1988) 161
8. For comprehensive reviews on DPP-IV inhibitors, see:. Villhauer E.B., Coppola G.M., and Hughes T.E. Annu. Rep. Med. Chem. 36 (2001) 191
9. Weber A.E. J. Med. Chem. 47 (2004) 4135
10. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., and Villhauer E.B. Biochemistry 38 (1999) 11597
11. Villhauer E.B., Brinkman J.A., Naderi G.B., Dunning B.E., Mangold B.L., Mone M.D., Russell M.E., Weldon S.C., and Hughes T.E. J. Med. Chem. 45 (2002) 2362
12. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
13. McIntyre J.A., and Castańer J. Drugs Future 29 (2004) 887
14. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.-P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
15. Sakashita H., Kitajima H., Nakamura M., Akahoshi F., and Hayashi Y. Bioorg. Med. Chem. Lett. 15 (2005) 2441
16. Sakashita H., Akahoshi F., Kitajima H., Tsutsumiuchi R., and Hayashi Y. Bioorg. Med. Chem. 14 (2006) 3662
17. Sakashita H., Akahoshi F., Yoshida T., Kitajima H., Hayashi Y., Ishii S., Takashina Y., Tsutsumiuchi R., and Ono S. Bioorg. Med. Chem. 15 (2007) 641
18. 50 values determined by logistic analysis.
19. Xu J., Wei L., Mathvink R.J., Edmondson S.D., Eiermann G.J., He H., Leone J.F., Leiting B., Lyons K.A., Marsilio F., Patel R.A., Patel S.B., Petrov A., Scapin G., Wu J.K., Thornberry N.A., and Weber A.E. Bioorg. Med. Chem. Lett. 16 (2006) 5373
20. Edmondson S.D., Mastracchio A., Mathvink R.J., He J., Harper B., Park Y.-J., Beconi M., Salvo J.D., Eiermann G.J., He H., Leiting B., Leone J.F., Levorse D.A., Lyons K., Patel R.A., Patel S.B., Petrov A., Scapin G., Shang J., Roy R.S., Smith A., Wu J.K., Xu S., Zhu B., Thornberry N.A., and Weber A.E. J. Med. Chem. 49 (2006) 3614
21. Tsai T.-Y., Coumar M.S., Hsu T., Hsieh H.-P., Chien C.-H., Chen C.-T., Chang C.-N., Lo Y.-K., Wu S.-H., Huang C.-Y., Huang Y.-W., Wang M.-H., Wu H.-Y., Lee H.-J., Chen X., Chao Y.-S., and Jiaang W.-T. Bioorg. Med. Chem. Lett. 16 (2006) 3268
22. Male Wistar rats (7-9 weeks of age) fasted overnight were used. Each compound of 17k, 21e, and 6 was dissolved in 0.5% hydroxypropylmethyl-cellulose and administered orally at a dose of 10 μmol/kg. At pre-administration and at 0.5, 1, 2, 3, 5, 7, and 9 h after administration, 0.1 mL of blood was collected from the jugular vein. After centrifugation, 10 μL of plasma was diluted 10-fold using buffer (0.003% Brij-35 containing PBS). 20 μL of the diluted plasma was used instead of 20 μL of the test substrate for the determination of DPP-IV inhibitory activity by fluorescence as described above.